Dual vs Triple Therapy Following ACS or PCI in Patients with Atrial Fibrillation
Journal of Clinical Outcomes Management. 2019 November;26(6):1-2
December 4, 2019|Journal of Clinical Outcomes Management
Lopes RD, Heizer G, Aronson R, et al; AUGUSTUS investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509-1524.
Applications for Clinical Practice
In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, dual therapy with a P2Y12 inhibitor and DOAC should be favored over a regimen that includes a vitamin K antagonist and/or aspirin.
—Taishi Hirai, MD, University of Missouri Medical Center, and John Blair, MD, University of Chicago Medical Center
